[vc_row content_width=”grid” css=”.vc_custom_1516178432909{padding-top: 80px !important;padding-bottom: 80px !important;}”][vc_column offset=”vc_col-lg-5 vc_col-md-12″][vc_single_image image=”7179″ img_size=”full”][\/vc_column][vc_column offset=”vc_col-lg-7 vc_col-md-12″ css=”.vc_custom_1516178424937{padding-right: 50px !important;padding-left: 50px !important;}”][vc_empty_space height=”25px”][vc_column_text]Dr. Rick Xu is a venture partner for Quan Capital. He also serves as Chief Medical officer of Oricell Therapeutics, graduated from Harbin Medical University. Upon completion of his residency, he started fellowship training major in Gastroenterology, at the Department of Internal Medicine, at Truman Medical Center in Kansas City.\u00a0 Thereafter, he received his Master of Science in Biology, Ph.D. in Biopharmaceuticals and completed his post-doc. training from Dr. William Jusko at the Department of Pharmaceutic Science, School of Pharmacy, SUNY at Buffalo.\u00a0 He started his career in pharmaceutical industry in 1991.\u00a0 Since then, he had worked for Sterling Winthrop, Pfizer, and Hoffman-La Roche, Genentech, respectively.\u00a0 During his ~30 years of industry career, working with teams, he successfully designed, engineered and developed two multi-billion dollars products, the PEGSYS and the Long Acting Filgrastim. Through his professional career, he has filed numerous of IND, NDAs and built extensive professional experiences in Oncology, CNS, virology and anti-infectious diseases.\u00a0 Since 2006, as Sr. Director, Expert Scientist of Translational Medicine in Oncology, Clinical Pharmacology, he has been primarily focusing on the global clinical drug development of immune oncology therapeutic products.\u00a0 His experiences involve various targets including: effector\u2019s priming\/induction; enhancing infiltration, recognition; and tumor cell killing based on either passive and\/or active immunization; and vaccination.\u00a0 He frequently received invitation to present at national \/ international conferences.\u00a0 He Joined the InnoCare Pharma as Chief Medical Officer in 2018.\u00a0 Additionally, he had been serving as advisor \/ consultant roles for numerous national and international scientific institutions and non-profit professional organizations.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"
[vc_row content_width=”grid” css=”.vc_custom_1516178432909{padding-top: 80px !important;padding-bottom: 80px !important;}”][vc_column offset=”vc_col-lg-5 vc_col-md-12″][vc_single_image image=”7179″ img_size=”full”][\/vc_column][vc_column offset=”vc_col-lg-7 vc_col-md-12″ css=”.vc_custom_1516178424937{padding-right: 50px !important;padding-left: 50px !important;}”][vc_empty_space height=”25px”][vc_column_text]Dr. Rick Xu…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":6552,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"full-width.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/7178"}],"collection":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/comments?post=7178"}],"version-history":[{"count":6,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/7178\/revisions"}],"predecessor-version":[{"id":8324,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/7178\/revisions\/8324"}],"up":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/6552"}],"wp:attachment":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/media?parent=7178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}